Zhaoke Ophthalmology-B (06622) rose more than 6%. As of press release, it rose 6.6% to HK$3.07, with a turnover of HK$1,148,800.
The Zhitong Finance App learned that Zhaoke Ophthalmology-B (06622) rose more than 6%. As of press release, it had risen 6.6% to HK$3.07, with a turnover of HK$1,148,800.
According to the news, Zhaoke Ophthalmology recently announced that new drug test applications for BRIMOCHOL PF and CARBACHOL PF have recently been approved by China's National Drug Administration. Based on the “Drug Clinical Trial Approval Notice” approved by the State Drug Administration, the company will conduct clinical trials on presbyopia subjects in China.
According to the announcement, BRIMOCHOL PF and Carbachol PF are preservative-free eye drops for pupil conditioning once a day, used as a treatment to correct loss of close vision due to presbyopia. In the VIVID Phase 2 study, both prescriptions reached the primary and secondary endpoints. Nine hours of close vision showed a three-level improvement, with no effect on farsighted vision. BRIMOCHOL PF and carbachol PF are well tolerated and have no serious side effects.